Commonly prescribed antidepressants associated with lower bone density in older men and women

The class of antidepressant medications known as selective serotonin reuptake inhibitors may be associated with an increased rate of bone loss in older men and women, according to two articles in the June 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Selective serotonin reuptake inhibitors (SSRIs) treat depression by inhibiting the protein that transports serotonin, a neurotransmitter involved in sleep and depression, according to background information in the articles. This protein has recently been discovered in bone as well, raising the possibility that SSRIs may affect bone density and the risk of fracture. SSRIs account for about 62 percent of antidepressant prescriptions in the United States, and are often prescribed to the elderly.

Susan J. Diem, M.D., M.P.H., University of Minnesota, Minneapolis, and colleagues studied 2,722 older women (average age 78.5 years) beginning in 1997 through 1999. At that time and again an average of 4.9 years later, researchers measured women’s total hip bone density and also that of two subregions. At each visit, the participants were asked to bring in all the medications they had used within the past two weeks, including SSRIs and tricyclic antidepressants, which work through a different mechanism.

A total of 198 (7.3 percent) of the women were SSRI users, 118 (4.3 percent) took tricyclic antidepressants and 2,406 (88.4 percent) took neither (those who took both were not included in the analysis). After the researchers adjusted for other factors affecting bone density and antidepressant use, including depression severity and calcium supplement use, bone mineral density at the hip decreased 0.82 percent in SSRI users. This compared with a decrease of 0.47 percent among those who used tricyclic antidepressants and also in those who did not take any antidepressants. Higher rates of bone loss were also observed at the two hip subregions among SSRI users.

“One potential explanation for our findings is that SSRI use may have a direct deleterious effect on bone,” the authors write. “This theory is supported by findings of in vitro and in vivo laboratory investigations.” Some data suggest that SSRIs may interfere with the function of osteoclasts and osteoblasts, cells responsible for the regular breaking down and rebuilding of bone in the body.

“Our findings suggest that, in this cohort, use of SSRIs is associated with increased rates of hip bone loss,” the authors conclude. Although some of this association may have occurred because women who were prescribed SSRIs were different from those who were not prescribed SSRIs, “further investigation of SSRI use and rates of change in bone mineral density in other populations with longer follow-up is warranted given the recent description of serotonin transporters in bone.”

In a related paper, Elizabeth M. Haney, M.D., of Oregon Health & Sciences University, Portland, and colleagues conducted a similar study with 5,995 men age 65 and older (average age 73.7). The men’s bone density at the hip, including subregions, and at the base of the spine were measured between 2000 and 2002. Participants were asked to bring all medications to their clinic visit, where they were also given a physical examination and asked about other health and lifestyle factors.

A total of 160 (2.7 percent) men reported using SSRIs, 99 (1.7 percent) reported using tricyclic antidepressants and 52 (0.9 percent) reported using trazodone, a third type of antidepressant. Total hip bone mineral density was 3.9 percent lower among SSRI users than among men who didn’t use any antidepressants. Similarly, spine bone mineral density was 5.9 percent lower among SSRI users than among non-users. There was no significant difference in either hip or spine density between men who took tricyclic antidepressants or trazodone and those who did not take antidepressants.

“These associations are biologically plausible and clinically important,” the authors conclude. “Because SSRI use is prevalent in the general population, our findings have a potentially important public health impact. If confirmed, people using SSRIs might be targeted for osteoporosis screening and preventive intervention.”

Source: JAMA and Archives Journals

Related stories:

'Stuffy nose' mouse: A promise to help treat 31 million with sinusitis
Mice with inflamed nasal tissue being tested at a Johns Hopkins laboratory may be unable to tell if something smells bad or good, but their sensory deficit is nothing to turn up a nose at.
Researchers grow human blood vessels in mice from adult progenitor cells
For the first time, researchers have successfully grown functional human blood vessels in mice using cells from adult human donors — an important step in developing clinical strategies to grow tissue, researchers report in Circulation Research: Journal of the American Heart Association.
Researchers uncover benefits of aspirin for treating osteoporosis
Researchers at the University of Southern California, School of Dentistry have uncovered the health benefits of aspirin in the fight against osteoporosis. Forty-four million Americans, 68 percent of whom are women, suffer from the debilitating effects of osteoporosis according to the National Institute of Health. One out of every two women and one in four men over 50 will have an osteoporosis-related fracture in their lifetime.
Resveratrol found to improve health, but not longevity in aging mice on standard diet
Scientists have found that the compound resveratrol slows age-related deterioration and functional decline of mice on a standard diet, but does not increase longevity when started at middle age. This study, conducted and supported in part by the National Institute on Aging (NIA), part of the National Institutes of Health, is a follow-up to 2006 findings that resveratrol improves health and longevity of overweight, aged mice. The report confirms previous results suggesting the compound, found naturally in foods like grapes and nuts, may mimic, in mice, some of the effects of dietary or calorie restriction, the most effective and reproducible way found to date to alleviate age-associated disease in mammals.
Red wine ingredient wards off effects of age on heart, bones, eyes and muscle
Large doses of a red wine ingredient can ward off many of the vagaries of aging in mice who begin taking it at midlife, according to a new report published online on July 3rd in Cell Metabolism, a Cell Press publication. Those health improvements of the chemical known as resveratrol—including cardiovascular benefits, greater motor coordination, reduced cataracts and better bone density—come without necessarily extending the animals' lifespan.
Researchers coat titanium with polymer to improve integration of joint replacements
Research at the Georgia Institute of Technology shows that coating a titanium implant with a new biologically inspired material enhances tissue healing, improves bone growth around the implant and strengthens the attachment and integration of the implant to the bone.
Simple ultrasound exam may predict osteoporosis risk
OAK BROOK, Ill. – An ultrasound exam of the heel may be able to predict if a woman is at heightened risk for fractures due to osteoporosis, according to a new multicenter study being published in the July issue of the journal Radiology. Along with certain risk factors, including age or recent fall, radiation-free ultrasound of the heel may be used to better select women who need further bone density testing, such as a dual-energy x-ray absorptiometry (DXA) exam.
Diabetes drug slows early-onset puberty in girls
In young girls at risk of early puberty and insulin resistance, the diabetes drug metformin delayed the onset of menstruation and decreased the development of insulin resistance, a risk factor for type 2 diabetes, according to a new study. The results were presented Monday, June 16, at The Endocrine Society's 90th Annual Meeting in San Francisco.

News discussion:

Medicine & Health news